HTG to Host Scientific Webinar Featuring Customer Use of the HTG Transcriptome Panel in Preclinical and Clinical Programs
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HTG Molecular Diagnostics (HTGM) will host a scientific webinar on June 23, 2022, titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research.” The session will feature Pete Ansell, Ph.D., from AbbVie, discussing challenges faced with FFPE clinical samples and the use of HTG’s Transcriptome Panel in biomarker strategies. Marian Navratil, Ph.D., will present on the HTP design and performance based on HTG’s EdgeSeq technology. This 60-minute webinar starts at 2:00 PM ET.
Details
News Market Reaction – HTGM
The recorded move for HTGM in the trading session of this news was -3.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TUCSON, Ariz., June 01, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it will be hosting a scientific webinar titled “Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research” on June 23, 2022.
This webinar will feature Pete Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie. Dr. Ansell will discuss how his team at AbbVie has overcome many challenges they have previously faced using FFPE clinical samples by integrating HTG’s innovative HTG Transcriptome Panel (HTP) into their biomarker strategies.
The presentation will be facilitated by Marian Navratil, Ph.D., Senior Vice President of Research and Development at HTG, who will highlight the design and performance of HTP based on HTG’s proprietary HTG EdgeSeq technology.
Details of the webinar are below:
| Date: | Thursday, June 23 |
| Time: | 2:00 PM Eastern Time |
| Duration: | 60 minutes |
| Access: | Click to Register |
About HTG:
HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.
Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com.
HTG Investor Contact:
Ashley Robinson
LifeSci Advisors
Phone: (617) 430-7577
Email: arr@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.